08:41 AM EST, 11/11/2024 (MT Newswires) -- Aethlon Medical ( AEMD ) said Monday that the first patient has been enrolled in an Australian clinical trial of its immunotherapeutic device Hemopurifier to treat patients with solid tumors.

The company said the trial will treat patients who have stable or progressive disease while receiving anti-PD-1 monotherapy, such as Keytruda or Opdivo.

Aethlon said the first patient will receive anti-PD-1 therapy within the next two months, when concentrations of extracellular vesicles and anti-tumor T cell activity will be measured.

Shares of Aethlon Medical ( AEMD ) were up 14% in recent premarket activity.